We are applying our TransCon technology to build a leading, fully integrated biopharmaceutical company with an independent pipeline of long-acting prodrug therapies that address unmet needs. In addition to our current pipeline of three rare disease endocrinology candidates, we have established oncology as our second therapeutic area of focus.
1Based on market data and Company estimates
2Excludes rights granted to VISEN Pharmaceuticals in Greater China
3Includes all indications
4Based on treatment of ~25% of the U.S. patient population of ~80,000 patients